Adult Brain Tumor Consortium (ABTC)

成人脑肿瘤联盟 (ABTC)

• 批准号: 7885812
• 负责人: STUART A GROSSMAN
• 金额: $ 74.27万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-01 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7885812
• 关键词: Adult; Antineoplastic Agents; Award; Biology; Biometry; Brain Neoplasms; Clinical Trials; Collaborations; Collection; Coupled; Data; Drug Kinetics; Funding; Image; Image Analysis; Institution; International; Laboratory Study; Leadership; Malignant neoplasm of central nervous system; Methodology; New Approaches to Brain Tumor Therapy Consortium; North American Brain Tumor Consortium; Operative Surgical Procedures; Pharmacodynamics; Pharmacologic Substance; Pharmacology; Phase; Primary Brain Neoplasms; Principal Investigator; Protocols documentation; Qualifying; Reporting; Reproduction spores; Research; Research Personnel; Site; Structure; Training; Translational Research; United States National Institutes of Health; base; design; effective therapy; experience; interdisciplinary approach; member; neuropathology; novel; novel strategies; novel therapeutics; skills

DESCRIPTION (provided by applicant): This application responds to RFA-CA-08-504 which is intended to continue support for Phase 1 and 2 treatment studies in adults with primary central nervous system cancers and to continue the activities that were funded initially under RFA CA-04-001. This single, consolidated application from the two currently funded separate adult brain tumor consortia: New Approaches to Brain Tumor Therapy (NABTT) and North American Brain Tumor Consortium (NABTC) is designed to maximize clinical trial efficiency and enhance support for translational research. The Adult Brain Tumor Consortium (ABTC) will capitalize on the scientific expertise and experience that has been nurtured during the previous award periods by retaining the majority of the NABTT and NABTC member institutions as well as clinical trial, pharmacology, biostatistics, and neuropathology leadership. The Co-Principal Investigators of the ABTC (Stuart Grossman and Michael Prados) have directed the activities of NABTT and NABTC since their inception in 1994. ABTC will utilize the skills and experience of The NABTT Operations Office (Stuart Grossman and Joy Fisher), the NABTC biostatistician (Kathleen Lamborn), pharmacologists from NABTT and NABTC (Jeff Supko and John Kuhn), and neuro-imaging (Greg Sorensen and Sarah Nelson) and neuropathology (Ken Aldape) experts. Based on predetermined criteria, the ABTC Steering Committee will evaluate potential member sites, dismiss underperforming member sites, and evaluate competitive applications and award funds for pharmacologic, imaging, and correlative biology research. ABTC's committee structure will focus on interactions with the NIH, SPOREs, cooperative groups, institutional translational research, pharmaceutical companies, and novel multidisciplinary approaches. An experienced and international External Advisory Board will provide valuable input to ABTC. This newly consolidated consortium will strive to develop more effective therapies for adult brain tumors by: 1) safely and efficiently introducing novel anticancer agents into the treatment of high grade primary brain tumors through the conduct of Phase 1-2 clinical trials, 2) Proactively seeking collaborations with other NCI-funded clinical trials mechanisms and researchers devoted to finding promising new treatment approaches for adult brain tumors; and 3) Incorporating pharmacokinetic and pharmacodynamic endpoints (including imaging and translational laboratory studies) as appropriate into Phase 1-2 studies.

描述（由申请人提供）：此申请对RFA-CA-08-504做出响应，该申请旨在继续支持初级中枢神经系统癌症成年人的第1阶段和2阶段治疗研究，并继续根据RFA CA-04-001资助的活动。这两个当前资助的单独的成人脑肿瘤联盟的单一合并应用：脑肿瘤治疗（NABTT）和北美脑肿瘤财团（NABTC）的新方法旨在最大化临床试验效率并提高对翻译研究的支持。成人脑肿瘤财团（ABTC）将利用在前一项奖励期间培养的科学专业知识和经验，通过保留大多数NABTT和NABTC成员机构以及临床试验，药理学，生物统计学和神经病理学领导才能。 The Co-Principal Investigators of the ABTC (Stuart Grossman and Michael Prados) have directed the activities of NABTT and NABTC since their inception in 1994. ABTC will utilize the skills and experience of The NABTT Operations Office (Stuart Grossman and Joy Fisher), the NABTC biostatistician (Kathleen Lamborn), pharmacologists from NABTT and NABTC （Jeff Supko和John Kuhn），以及神经模仿（Greg Sorensen和Sarah Nelson）和Neuropathology（Ken Aldape）专家。基于预定的标准，ABTC指导委员会将评估潜在的成员站点，驳回表现不佳的会员站点，并评估竞争性应用程序和授予药物，成像和相关生物学研究的资金。 ABTC的委员会结构将集中于与NIH，孢子，合作团体，机构翻译研究，制药公司和新颖的多学科方法的互动。经验丰富的国际外部顾问委员会将为ABTC提供宝贵的意见。 This newly consolidated consortium will strive to develop more effective therapies for adult brain tumors by: 1) safely and efficiently introducing novel anticancer agents into the treatment of high grade primary brain tumors through the conduct of Phase 1-2 clinical trials, 2) Proactively seeking collaborations with other NCI-funded clinical trials mechanisms and researchers devoted to finding promising new treatment approaches for adult brain tumors; 3）将适当的药代动力学和药效动力学终点（包括成像和翻译实验室研究）纳入1-2阶段研究。